A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
All content for The Life Challenges Podcast is the property of Christian Life Resources and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
What’s Trending? Big Beautiful Bill, Role of Adoption, Infant Pain, and Lab Grown Sperm and Egg
The Life Challenges Podcast
36 minutes
3 months ago
What’s Trending? Big Beautiful Bill, Role of Adoption, Infant Pain, and Lab Grown Sperm and Egg
When science and policy push the boundaries of God's design, where do Christians stand? In this thought-provoking exploration of today's most challenging bioethical issues, we dive deep into recent developments that force us to confront fundamental questions about life, reproduction, and human dignity. The conversation begins with an examination of the recent legislation defunding Planned Parenthood and its potential ramifications. While the organization claims this could force closure of on...
The Life Challenges Podcast
A new generic abortion pill hits the market, IVF access expands, and home births surge—each framed as progress, each carrying hidden costs. We pull apart the headlines and ask the harder question: what protects vulnerable lives when policy moves faster than moral clarity? First, we unpack the FDA’s approval of another mifepristone generic and why “identical formulation” doesn’t settle the ethical debate. Safety talk often skims maternal side effects while ignoring the unborn child’s near‑cer...
